Drebrin pp 203-223 | Cite as

Drebrin in Alzheimer’s Disease

Chapter
First Online:
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1006)

Abstract

Alzheimer’s disease (AD) is a neurodegenerative disorder accompanied by severe progressive memory and cognitive impairment. The brain of AD patients has an abundance of two abnormal structures, amyloid plaques (senile plaques) and neurofibrillary tangles. In addition, drebrin loss is another hallmark of AD brains, which is a common feature in the brain of both AD patients and AD mouse models. Strong evidence from human genetics and transgenic mouse models has indicated that amyloid β (Aβ) is part of the etiology and pathogenesis of AD. Recently, it has become clear that synaptic dysfunction, including reduced synaptic transmission and loss of dendritic spines, occurs prior to the formation of amyloid plaques and neuronal cell loss. Furthermore, immunohistochemistry using postmortem human brains and AD mouse models has shown that drebrin loss in postsynaptic sites occurs earlier than the presynaptic change in AD brains. In addition, dysregulation of glutamate receptor trafficking and the p21-activated kinase/LIM kinase pathway has been observed in AD brains. It is now believed that soluble Aβ oligomers, namely, Aβ-derived diffusible ligands (ADDLs), but not insoluble Aβ aggregation mediates Aβ toxicity. ADDLs bind to the postsynaptic site and induce the aberrant morphology and density of dendritic spines. Consistent with the AD mouse models, the surface expression of glutamate receptors decreases after ADDL exposure. Importantly, the ADDL-induced drebrin loss in dendritic spines occurs prior to aberrations in dendritic spine morphology and density. These observations indicate that drebrin loss in dendritic spines occurs at the prodromal stage of AD, before the density and morphology of dendritic spines change. Quantitation of drebrin may be a possible tool for diagnosing the prodromal stage of AD, before dementia development in AD.

Keywords

Drebrin Cofilin α-Amino-3-hydroxy-5-methyl-4-isoxaxole propionic acid receptor N-Methyl-D-aspartate receptor Alzheimer’s disease Aβ-derived diffusible ligands Synaptic dysfunction 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgment

We would like to thank Dr. Masaki Ikeda for his comments and useful discussion of the manuscript.

References

  1. Aoki C, Mahadomrongkul V, Fujisawa S, Habersat R, Shirao T (2007) Chemical and morphological alterations of spines within the hippocampus and entorhinal cortex precede the onset of Alzheimer's disease pathology in double knock-in mice. J Comp Neurol 505:352–362PubMedPubMedCentralCrossRefGoogle Scholar
  2. Aoki C, Kojima N, Sabaliauskas N et al (2009a) Drebrin a knockout eliminates the rapid form of homeostatic synaptic plasticity at excitatory synapses of intact adult cerebral cortex. J Comp Neurol 517:105–121PubMedPubMedCentralCrossRefGoogle Scholar
  3. Aoki C, Lee J, Nedelescu H, Ahmed T, Ho A, Shen J (2009b) Increased levels of NMDA receptor NR2A subunits at pre- and postsynaptic sites of the hippocampal CA1: an early response to conditional double knockout of presenilin 1 and 2. J Comp Neurol 517:512–523PubMedPubMedCentralCrossRefGoogle Scholar
  4. Arber S, Barbayannis FA, Hanser H, Schneider C, Stanyon CA, Bernard O, Caroni P (1998) Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase. Nature 393:805–809PubMedCrossRefGoogle Scholar
  5. Bamburg JR, Wiggan OP (2002) ADF/cofilin and actin dynamics in disease. Trends Cell Biol 12:598–605PubMedCrossRefGoogle Scholar
  6. Battaglia F, Wang HY, Ghilardi MF, Gashi E, Quartarone A, Friedman E, Nixon RA (2007) Cortical plasticity in Alzheimer's disease in humans and rodents. Biol Psychiatry 62:1405–1412PubMedCrossRefGoogle Scholar
  7. Beique JC, Lin DT, Kang MG, Aizawa H, Takamiya K, Huganir RL (2006) Synapse-specific regulation of AMPA receptor function by PSD-95. Proc Natl Acad Sci U S A 103:19535–19540PubMedPubMedCentralCrossRefGoogle Scholar
  8. Bosch M, Castro J, Saneyoshi T, Matsuno H, Sur M, Hayashi Y (2014) Structural and molecular remodeling of dendritic spine substructures during long-term potentiation. Neuron 82:444–459PubMedPubMedCentralCrossRefGoogle Scholar
  9. Busse A, Hensel A, Guhne U, Angermeyer MC, Riedel-Heller SG (2006) Mild cognitive impairment: long-term course of four clinical subtypes. Neurology 67:2176–2185PubMedCrossRefGoogle Scholar
  10. Calon F, Lim GP, Yang F et al (2004) Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 43:633–645PubMedPubMedCentralCrossRefGoogle Scholar
  11. Chang EH, Savage MJ, Flood DG, Thomas JM, Levy RB, Mahadomrongkul V, Shirao T, Aoki C, Huerta PT (2006) AMPA receptor downscaling at the onset of Alzheimer's disease pathology in double knockin mice. Proc Natl Acad Sci U S A 103:3410–3415PubMedPubMedCentralCrossRefGoogle Scholar
  12. Chapman PF, White GL, Jones MW et al (1999) Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 2:271–276PubMedCrossRefGoogle Scholar
  13. Chimura T, Launey T, Yoshida N (2015) Calpain-mediated degradation of Drebrin by Excitotoxicity in vitro and in vivo. PLoS One 10:e0125119PubMedPubMedCentralCrossRefGoogle Scholar
  14. Chishti MA, Yang DS, Janus C et al (2001) Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 276:21562–21570PubMedCrossRefGoogle Scholar
  15. Conquer JA, Tierney MC, Zecevic J, Bettger WJ, Fisher RH (2000) Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. Lipids 35:1305–1312PubMedCrossRefGoogle Scholar
  16. Cotrena C, Branco LD, Shansis FM, Fonseca RP (2016) Executive function impairments in depression and bipolar disorder: association with functional impairment and quality of life. J Affect Disord 190:744–753PubMedCrossRefGoogle Scholar
  17. Counts SE, Nadeem M, Lad SP, Wuu J, Mufson EJ (2006) Differential expression of synaptic proteins in the frontal and temporal cortex of elderly subjects with mild cognitive impairment. J Neuropathol Exp Neurol 65:592–601PubMedCrossRefGoogle Scholar
  18. De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, Klein WL (2007) Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 282:11590–11601PubMedCrossRefGoogle Scholar
  19. Decker H, Jurgensen S, Adrover MF et al (2010) N-methyl-D-aspartate receptors are required for synaptic targeting of Alzheimer’s toxic amyloid-beta peptide oligomers. J Neurochem 115:1520–1529PubMedCrossRefGoogle Scholar
  20. DeKosky ST, Scheff SW (1990) Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol 27:457–464PubMedCrossRefGoogle Scholar
  21. Ehrlich I, Klein M, Rumpel S, Malinow R (2007) PSD-95 is required for activity-driven synapse stabilization. Proc Natl Acad Sci U S A 104:4176–4181PubMedPubMedCentralCrossRefGoogle Scholar
  22. El-Husseini AE, Schnell E, Chetkovich DM, Nicoll RA, Bredt DS (2000) PSD-95 involvement in maturation of excitatory synapses. Science 290:1364–1368PubMedGoogle Scholar
  23. Fischer P, Jungwirth S, Zehetmayer S, Weissgram S, Hoenigschnabl S, Gelpi E, Krampla W, Tragl KH (2007) Conversion from subtypes of mild cognitive impairment to Alzheimer dementia. Neurology 68:288–291PubMedCrossRefGoogle Scholar
  24. Flood DG, Reaume AG, Dorfman KS et al (2002) FAD mutant PS-1 gene-targeted mice: increased a beta 42 and a beta deposition without APP overproduction. Neurobiol Aging 23:335–348PubMedCrossRefGoogle Scholar
  25. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198Google Scholar
  26. Francis YI, Fà M, Ashraf H, Zhang H, Staniszewski A, Latchman DS, Arancio O (2009) Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease. J Alzheimers Dis 18:131–139PubMedCrossRefGoogle Scholar
  27. Freir DB, Nicoll AJ, Klyubin I et al (2011) Interaction between prion protein and toxic amyloid beta assemblies can be therapeutically targeted at multiple sites. Nat Commun 2:336PubMedPubMedCentralCrossRefGoogle Scholar
  28. Fukazawa Y, Saitoh Y, Ozawa F, Ohta Y, Mizuno K, Inokuchi K (2003) Hippocampal LTP is accompanied by enhanced F-actin content within the dendritic spine that is essential for late LTP maintenance in vivo. Neuron 38:447–460PubMedCrossRefGoogle Scholar
  29. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL (2003) Alzheimer's disease-affected brain: presence of oligomeric a beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A 100:10417–10422PubMedPubMedCentralCrossRefGoogle Scholar
  30. Gräff J, Tsai LH (2013) Histone acetylation: molecular mnemonics on the chromatin. Nat Rev Neurosci 14:97–111PubMedCrossRefGoogle Scholar
  31. Gräff J, Rei D, Guan JS et al (2012) An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 483:222–226PubMedPubMedCentralCrossRefGoogle Scholar
  32. Grintsevich EE, Reisler E (2014) Drebrin inhibits cofilin-induced severing of F-actin. Cytoskeleton 71:472–483PubMedPubMedCentralCrossRefGoogle Scholar
  33. Guo Q, Wang Z, Li H, Wiese M, Zheng H (2012) APP physiological and pathophysiological functions: insights from animal models. Cell Res 22:78–89PubMedCrossRefGoogle Scholar
  34. Hardy JA, Higgins GA (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256:184–185PubMedCrossRefGoogle Scholar
  35. Harigaya Y, Shoji M, Shirao T, Hirai S (1996) Disappearance of actin-binding protein, drebrin, from hippocampal synapses in Alzheimer's disease. J Neurosci Res 43:87–92PubMedCrossRefGoogle Scholar
  36. Hatanpää K, Isaacs KR, Shirao T, Brady DR, Rapoport SI (1999) Loss of proteins regulating synaptic plasticity in normal aging of the human brain and in Alzheimer disease. J Neuropathol Exp Neurol 58:637–643PubMedCrossRefGoogle Scholar
  37. He K, Song L, Cummings LW, Goldman J, Huganir RL, Lee HK (2009) Stabilization of Ca2+−permeable AMPA receptors at perisynaptic sites by GluR1-S845 phosphorylation. Proc Natl Acad Sci U S A 106:20033–20038PubMedPubMedCentralCrossRefGoogle Scholar
  38. Head E, Silverman W, Patterson D, Lott IT (2012) Aging and down syndrome. Curr Gerontol Geriatr Res 2012:412536PubMedPubMedCentralCrossRefGoogle Scholar
  39. Hsia AY, Masliah E, McConlogue L et al (1999) Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A 96:3228–3233PubMedPubMedCentralCrossRefGoogle Scholar
  40. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274:99–102PubMedCrossRefGoogle Scholar
  41. Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R (2006) AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 52:831–843PubMedPubMedCentralCrossRefGoogle Scholar
  42. Inghilleri M, Conte A, Frasca V, Scaldaferri N, Gilio F, Santini M, Fabbrini G, Prencipe M, Berardelli A (2006) Altered response to rTMS in patients with Alzheimer's disease. Clin Neurophysiol 117:103–109PubMedCrossRefGoogle Scholar
  43. Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT (1997) APPSw transgenic mice develop age-related a beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol 56:965–973PubMedCrossRefGoogle Scholar
  44. Ishizuka Y, Shimizu H, Takagi E, Kato M, Yamagata H, Mikuni M, Shirao T (2014) Histone deacetylase mediates the decrease in drebrin cluster density induced by amyloid beta oligomers. Neurochem Int 76:114–121PubMedCrossRefGoogle Scholar
  45. Jacobsen JS, Wu CC, Redwine JM et al (2006) Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 103:5161–5166PubMedPubMedCentralCrossRefGoogle Scholar
  46. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486–489PubMedCrossRefGoogle Scholar
  47. Kilgore M, Miller CA, Fass DM, Hennig KM, Haggarty SJ, Sweatt JD, Rumbaugh G (2010) Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 35:870–880PubMedCrossRefGoogle Scholar
  48. Kim HW, Rapoport SI, Rao JS (2010) Altered expression of apoptotic factors and synaptic markers in postmortem brain from bipolar disorder patients. Neurobiol Dis 37:596–603PubMedCrossRefGoogle Scholar
  49. Kim T, Vidal GS, Djurisic M, William CM, Birnbaum ME, Garcia KC, Hyman BT, Shatz CJ (2013) Human LilrB2 is a beta-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer's model. Science 341:1399–1404PubMedCrossRefGoogle Scholar
  50. Koch G, Di Lorenzo F, Bonni S, Ponzo V, Caltagirone C, Martorana A (2012) Impaired LTP- but not LTD-like cortical plasticity in Alzheimer's disease patients. J Alzheimers Dis 31:593–599PubMedGoogle Scholar
  51. Kojima N, Hanamura K, Yamazaki H, Ikeda T, Itohara S, Shirao T (2010) Genetic disruption of the alternative splicing of drebrin gene impairs context-dependent fear learning in adulthood. Neuroscience 165:138–150PubMedCrossRefGoogle Scholar
  52. Kojima N, Yasuda H, Hanamura K, Ishizuka Y, Sekino Y, Shirao T (2016) Drebrin a regulates hippocampal LTP and hippocampus-dependent fear learning in adult mice. Neuroscience 324:218–226PubMedCrossRefGoogle Scholar
  53. Kurup P, Zhang Y, Xu J, Venkitaramani DV, Haroutunian V, Greengard P, Nairn AC, Lombroso PJ (2010) Abeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61. J Neurosci 30:5948–5957PubMedPubMedCentralCrossRefGoogle Scholar
  54. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL (2007) Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 27:796–807PubMedCrossRefGoogle Scholar
  55. Lambert MP, Barlow AK, Chromy BA et al (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95:6448–6453PubMedPubMedCentralCrossRefGoogle Scholar
  56. Lanz TA, Carter DB, Merchant KM (2003) Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype. Neurobiol Dis 13:246–253PubMedCrossRefGoogle Scholar
  57. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457:1128–1132PubMedPubMedCentralCrossRefGoogle Scholar
  58. Lee D, Aoki C (2012) Presenilin conditional double knockout mice exhibit decreases in drebrin a at hippocampal CA1 synapses. Synapse 66:870–879PubMedPubMedCentralCrossRefGoogle Scholar
  59. Lew J, Huang QQ, Qi Z, Winkfein RJ, Aebersold R, Hunt T, Wang JH (1994) A brain-specific activator of cyclin-dependent kinase 5. Nature 371:423–426PubMedCrossRefGoogle Scholar
  60. Liu SJ, Gasperini R, Foa L, Small DH (2010) Amyloid-beta decreases cell-surface AMPA receptors by increasing intracellular calcium and phosphorylation of GluR2. J Alzheimers Dis 21:655–666PubMedCrossRefGoogle Scholar
  61. Mahadomrongkul V, Huerta PT, Shirao T, Aoki C (2005) Stability of the distribution of spines containing drebrin a in the sensory cortex layer I of mice expressing mutated APP and PS1 genes. Brain Res 1064:66–74PubMedCrossRefGoogle Scholar
  62. Man HY, Sekine-Aizawa Y, Huganir RL (2007) Regulation of {alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor trafficking through PKA phosphorylation of the Glu receptor 1 subunit. Proc Natl Acad Sci U S A 104:3579–3584PubMedPubMedCentralCrossRefGoogle Scholar
  63. Mann DM, Pickering-Brown SM, Takeuchi A, Iwatsubo T, Members of the Familial Alzheimer's Disease Pathology Study Group (2001) Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer's disease. Am J Pathol 158:2165–2175PubMedPubMedCentralCrossRefGoogle Scholar
  64. Migaud M, Charlesworth P, Dempster M et al (1998) Enhanced long-term potentiation and impaired learning in mice with mutant postsynaptic density-95 protein. Nature 396:433–439PubMedCrossRefGoogle Scholar
  65. Minano-Molina AJ, Espana J, Martin E, Barneda-Zahonero B, Fado R, Sole M, Trullas R, Saura CA, Rodriguez-Alvarez J (2011) Soluble oligomers of amyloid-beta peptide disrupt membrane trafficking of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor contributing to early synapse dysfunction. J Biol Chem 286:27311–27321PubMedPubMedCentralCrossRefGoogle Scholar
  66. Mizui T, Sekino Y, Yamazaki H, Ishizuka Y, Takahashi H, Kojima N, Kojima M, Shirao T (2014) Myosin II ATPase activity mediates the long-term potentiation-induced exodus of stable F-actin bound by drebrin a from dendritic spines. PLoS One 9:e85367PubMedPubMedCentralCrossRefGoogle Scholar
  67. Moehlmann T, Winkler E, Xia X et al (2002) Presenilin-1 mutations of leucine 166 equally affect the generation of the notch and APP intracellular domains independent of their effect on Abeta 42 production. Proc Natl Acad Sci U S A 99:8025–8030PubMedPubMedCentralCrossRefGoogle Scholar
  68. Montine TJ, Morrow JD (2005) Fatty acid oxidation in the pathogenesis of Alzheimer's disease. Am J Pathol 166:1283–1289PubMedPubMedCentralCrossRefGoogle Scholar
  69. Moult PR, Gladding CM, Sanderson TM, Fitzjohn SM, Bashir ZI, Molnar E, Collingridge GL (2006) Tyrosine phosphatases regulate AMPA receptor trafficking during metabotropic glutamate receptor-mediated long-term depression. J Neurosci 26:2544–2554PubMedCrossRefGoogle Scholar
  70. Murachi T, Tanaka K, Hatanaka M, Murakami T (1980) Intracellular Ca2+−dependent protease (calpain) and its high-molecular-weight endogenous inhibitor (calpastatin). Adv Enzym Regul 19:407–424CrossRefGoogle Scholar
  71. Oh MC, Derkach VA, Guire ES, Soderling TR (2006) Extrasynaptic membrane trafficking regulated by GluR1 serine 845 phosphorylation primes AMPA receptors for long-term potentiation. J Biol Chem 281:752–758PubMedCrossRefGoogle Scholar
  72. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH (1999) Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402:615–622PubMedCrossRefGoogle Scholar
  73. Petersen RC, Morris JC (2005) Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol 62:1160–1163. discussion 1167PubMedCrossRefGoogle Scholar
  74. Pimplikar SW, Nixon RA, Robakis NK, Shen J, Tsai LH (2010) Amyloid-independent mechanisms in Alzheimer's disease pathogenesis. J Neurosci 30:14946–14954PubMedPubMedCentralCrossRefGoogle Scholar
  75. Prince M, Comas-Herrera A, Knapp M, Guerchet M, Karagiannidou M (2016) Improving healthcare for people living with dementia: coverage, quality and costs now and in the future. In: World Alzheimer Report 2016Google Scholar
  76. Rao MV, Mohan PS, Peterhoff CM et al (2008) Marked calpastatin (CAST) depletion in Alzheimer's disease accelerates cytoskeleton disruption and neurodegeneration: neuroprotection by CAST overexpression. J Neurosci 28:12241–12254PubMedPubMedCentralCrossRefGoogle Scholar
  77. Reaume AG, Howland DS, Trusko SP, Savage MJ, Lang DM, Greenberg BD, Siman R, Scott RW (1996) Enhanced amyloidogenic processing of the beta-amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer's disease mutations and a humanized Abeta sequence. J Biol Chem 271:23380–23388PubMedCrossRefGoogle Scholar
  78. Ricobaraza A, Cuadrado-Tejedor M, Perez-Mediavilla A, Frechilla D, Del Rio J, Garcia-Osta A (2009) Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology 34:1721–1732PubMedCrossRefGoogle Scholar
  79. Ricobaraza A, Cuadrado-Tejedor M, Marco S, Perez-Otano I, Garcia-Osta A (2012) Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. Hippocampus 22:1040–1050PubMedCrossRefGoogle Scholar
  80. Rogaev EI, Sherrington R, Rogaeva EA et al (1995) Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376:775–778PubMedCrossRefGoogle Scholar
  81. Rossiter JP, Anderson LL, Yang F, Cole GM (2000) Caspase-cleaved actin (fractin) immunolabelling of Hirano bodies. Neuropathol Appl Neurobiol 26:342–346PubMedCrossRefGoogle Scholar
  82. Saito K, Elce JS, Hamos JE, Nixon RA (1993) Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc Natl Acad Sci U S A 90:2628–2632PubMedPubMedCentralCrossRefGoogle Scholar
  83. Salem N Jr, Litman B, Kim HY, Gawrisch K (2001) Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 36:945–959PubMedCrossRefGoogle Scholar
  84. Saura CA, Choi SY, Beglopoulos V et al (2004) Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 42:23–36PubMedCrossRefGoogle Scholar
  85. Schnell E, Sizemore M, Karimzadegan S, Chen L, Bredt DS, Nicoll RA (2002) Direct interactions between PSD-95 and stargazin control synaptic AMPA receptor number. Proc Natl Acad Sci U S A 99:13902–13907PubMedPubMedCentralCrossRefGoogle Scholar
  86. Sekino Y, Tanaka S, Hanamura K, Yamazaki H, Sasagawa Y, Xue Y, Hayashi K, Shirao T (2006) Activation of N-methyl-D-aspartate receptor induces a shift of drebrin distribution: disappearance from dendritic spines and appearance in dendritic shafts. Mol Cell Neurosci 31:493–504PubMedCrossRefGoogle Scholar
  87. Sekino Y, Kojima N, Shirao T (2007) Role of actin cytoskeleton in dendritic spine morphogenesis. Neurochem Int 51:92–104PubMedCrossRefGoogle Scholar
  88. Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 298:789–791PubMedCrossRefGoogle Scholar
  89. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL (2007) Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27:2866–2875PubMedCrossRefGoogle Scholar
  90. Sherrington R, Rogaev EI, Liang Y et al (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375:754–760PubMedCrossRefGoogle Scholar
  91. Shim KS, Lubec G (2002) Drebrin, a dendritic spine protein, is manifold decreased in brains of patients with Alzheimer's disease and down syndrome. Neurosci Lett 324:209–212PubMedCrossRefGoogle Scholar
  92. Siman R, Reaume AG, Savage MJ, Trusko S, Lin YG, Scott RW, Flood DG (2000) Presenilin-1 P264L knock-in mutation: differential effects on abeta production, amyloid deposition, and neuronal vulnerability. J Neurosci 20:8717–8726PubMedGoogle Scholar
  93. Snyder EM, Nong Y, Almeida CG et al (2005) Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8:1051–1058PubMedCrossRefGoogle Scholar
  94. Sosa-Ortiz AL, Acosta-Castillo I, Prince MJ (2012) Epidemiology of dementias and Alzheimer’s disease. Arch Med Res 43:600–608PubMedCrossRefGoogle Scholar
  95. Steiner H, Duff K, Capell A et al (1999) A loss of function mutation of presenilin-2 interferes with amyloid beta-peptide production and notch signaling. J Biol Chem 274:28669–28673PubMedCrossRefGoogle Scholar
  96. Takahashi H, Sekino Y, Tanaka S, Mizui T, Kishi S, Shirao T (2003) Drebrin-dependent actin clustering in dendritic filopodia governs synaptic targeting of postsynaptic density-95 and dendritic spine morphogenesis. J Neurosci 23:6586–6595PubMedGoogle Scholar
  97. Takahashi H, Mizui T, Shirao T (2006) Down-regulation of drebrin a expression suppresses synaptic targeting of NMDA receptors in developing hippocampal neurones. J Neurochem 97(Suppl 1):110–115PubMedCrossRefGoogle Scholar
  98. Takahashi H, Yamazaki H, Hanamura K, Sekino Y, Shirao T (2009) Activity of the AMPA receptor regulates drebrin stabilization in dendritic spine morphogenesis. J Cell Sci 122:1211–1219PubMedCrossRefGoogle Scholar
  99. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572–580PubMedCrossRefGoogle Scholar
  100. Tully AM, Roche HM, Doyle R, Fallon C, Bruce I, Lawlor B, Coakley D, Gibney MJ (2003) Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control study. Br J Nutr 89:483–489PubMedCrossRefGoogle Scholar
  101. Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A, Wisniewski T, Gunther EC, Strittmatter SM (2012) Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci 15:1227–1235PubMedPubMedCentralCrossRefGoogle Scholar
  102. Wang HY, Lee DH, Davis CB, Shank RP (2000) Amyloid peptide Abeta(1–42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors. J Neurochem 75:1155–1161PubMedCrossRefGoogle Scholar
  103. Wang Y, Shibasaki F, Mizuno K (2005) Calcium signal-induced cofilin dephosphorylation is mediated by slingshot via calcineurin. J Biol Chem 280:12683–12689PubMedCrossRefGoogle Scholar
  104. Worth DC, Daly CN, Geraldo S, Oozeer F, Gordon-Weeks PR (2013) Drebrin contains a cryptic F-actin-bundling activity regulated by Cdk5 phosphorylation. J Cell Biol 202:793–806PubMedPubMedCentralCrossRefGoogle Scholar
  105. Wu HY, Hudry E, Hashimoto T et al (2010) Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. J Neurosci 30:2636–2649PubMedPubMedCentralCrossRefGoogle Scholar
  106. Xu J, Chatterjee M, Baguley TD et al (2014) Inhibitor of the tyrosine phosphatase STEP reverses cognitive deficits in a mouse model of Alzheimer's disease. PLoS Biol 12:e1001923PubMedPubMedCentralCrossRefGoogle Scholar
  107. Yang F, Sun X, Beech W, Teter B, Wu S, Sigel J, Vinters HV, Frautschy SA, Cole GM (1998a) Antibody to caspase-cleaved actin detects apoptosis in differentiated neuroblastoma and plaque-associated neurons and microglia in Alzheimer's disease. Am J Pathol 152:379–389PubMedPubMedCentralGoogle Scholar
  108. Yang N, Higuchi O, Ohashi K, Nagata K, Wada A, Kangawa K, Nishida E, Mizuno K (1998b) Cofilin phosphorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization. Nature 393:809–812PubMedCrossRefGoogle Scholar
  109. Yu H, Saura CA, Choi SY et al (2001) APP processing and synaptic plasticity in presenilin-1 conditional knockout mice. Neuron 31:713–726PubMedCrossRefGoogle Scholar
  110. Zhang Y, Venkitaramani DV, Gladding CM, Zhang Y, Kurup P, Molnar E, Collingridge GL, Lombroso PJ (2008) The tyrosine phosphatase STEP mediates AMPA receptor endocytosis after metabotropic glutamate receptor stimulation. J Neurosci 28:10561–10566PubMedPubMedCentralCrossRefGoogle Scholar
  111. Zhang Y, Kurup P, Xu J et al (2010) Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer's disease mouse model. Proc Natl Acad Sci U S A 107:19014–19019PubMedPubMedCentralCrossRefGoogle Scholar
  112. Zhang Y, Kurup P, Xu J, Anderson GM, Greengard P, Nairn AC, Lombroso PJ (2011) Reduced levels of the tyrosine phosphatase STEP block beta amyloid-mediated GluA1/GluA2 receptor internalization. J Neurochem 119:664–672PubMedPubMedCentralCrossRefGoogle Scholar
  113. Zhao L, Ma QL, Calon F et al (2006) Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat Neurosci 9:234–242PubMedCrossRefGoogle Scholar
  114. Zhao WQ, Santini F, Breese R et al (2010) Inhibition of calcineurin-mediated endocytosis and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors prevents amyloid beta oligomer-induced synaptic disruption. J Biol Chem 285:7619–7632PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan KK 2017

Authors and Affiliations

  1. 1.Department of Neurobiology and BehaviorGunma University Graduate School of MedicineMaebashiJapan

Personalised recommendations